Compare OGEN & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | SXTP |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.7M |
| IPO Year | N/A | 2023 |
| Metric | OGEN | SXTP |
|---|---|---|
| Price | $0.85 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.40 |
| AVG Volume (30 Days) | 47.7K | ★ 57.4K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,364,945.00 |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 202.10 |
| 52 Week Low | $0.82 | $0.85 |
| 52 Week High | $18.90 | $12.45 |
| Indicator | OGEN | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 30.26 | 35.84 |
| Support Level | $0.84 | $0.96 |
| Resistance Level | $1.06 | $1.12 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.15 | 48.39 |
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.